Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Corrigendum to "A consensus introduction to serum replacements and serum-free media for cellular therapies" [Cytotherapy 19 (2017) 155-169].

Karnieli O, Friedner OM, Allickson JG, Zhang N, Jung S, Fiorentini D, Abraham E, Eaker SS, Yong TK, Chan A, Griffiths S, Wehn AK, Oh S, Karnieli O.

Cytotherapy. 2018 Feb;20(2):271. doi: 10.1016/j.jcyt.2017.11.007. Epub 2017 Dec 6. No abstract available.

PMID:
29223535
2.

A consensus introduction to serum replacements and serum-free media for cellular therapies.

Karnieli O, Friedner OM, Allickson JG, Zhang N, Jung S, Fiorentini D, Abraham E, Eaker SS, Yong TK, Chan A, Griffiths S, Wehn AK, Oh S, Karnieli O.

Cytotherapy. 2017 Feb;19(2):155-169. doi: 10.1016/j.jcyt.2016.11.011. Epub 2016 Dec 22. Review. Erratum in: Cytotherapy. 2017 Dec 6;:.

PMID:
28017599
3.

Managing particulates in cell therapy: Guidance for best practice.

Clarke D, Stanton J, Powers D, Karnieli O, Nahum S, Abraham E, Parisse JS, Oh S.

Cytotherapy. 2016 Sep;18(9):1063-76. doi: 10.1016/j.jcyt.2016.05.011. Epub 2016 Jul 12. Review.

PMID:
27426934
4.

Concise Review: Process Development Considerations for Cell Therapy.

Campbell A, Brieva T, Raviv L, Rowley J, Niss K, Brandwein H, Oh S, Karnieli O.

Stem Cells Transl Med. 2015 Oct;4(10):1155-63. doi: 10.5966/sctm.2014-0294. Epub 2015 Aug 27. Review.

5.

Critical elements in the development of cell therapy potency assays for ischemic conditions.

Porat Y, Abraham E, Karnieli O, Nahum S, Woda J, Zylberberg C.

Cytotherapy. 2015 Jul;17(7):817-31. doi: 10.1016/j.jcyt.2014.08.014. Epub 2015 Feb 26. Review.

PMID:
25728414
6.

Concise review: guidance in developing commercializable autologous/patient-specific cell therapy manufacturing.

Eaker S, Armant M, Brandwein H, Burger S, Campbell A, Carpenito C, Clarke D, Fong T, Karnieli O, Niss K, Van't Hof W, Wagey R.

Stem Cells Transl Med. 2013 Nov;2(11):871-83. doi: 10.5966/sctm.2013-0050. Epub 2013 Oct 7. Review.

7.

Managing particulates in cellular therapy.

Clarke D, Harati D, Martin J, Rowley J, Keller J, McCaman M, Carrion M, Karnieli O, Maziarz R, Perry R, Oh S, Stanton J.

Cytotherapy. 2012 Oct;14(9):1032-40. doi: 10.3109/14653249.2012.706709. Epub 2012 Aug 17. Review.

PMID:
22900960
8.

Canine procalcitonin messenger RNA expression.

Kuzi S, Aroch I, Peleg K, Karnieli O, Klement E, Dank G.

J Vet Diagn Invest. 2008 Sep;20(5):629-33.

PMID:
18776098
9.

Enhancement of hybridoma formation, clonability and cell proliferation in a nanoparticle-doped aqueous environment.

Gavrilov-Yusim N, Hahiashvili E, Tashker M, Yavelsky V, Karnieli O, Lobel L.

BMC Biotechnol. 2008 Jan 14;8:3. doi: 10.1186/1472-6750-8-3.

10.

Generation of insulin-producing cells from human bone marrow mesenchymal stem cells by genetic manipulation.

Karnieli O, Izhar-Prato Y, Bulvik S, Efrat S.

Stem Cells. 2007 Nov;25(11):2837-44. Epub 2007 Jul 5.

11.

Reversal of hyperglycemia in mice by using human expandable insulin-producing cells differentiated from fetal liver progenitor cells.

Zalzman M, Gupta S, Giri RK, Berkovich I, Sappal BS, Karnieli O, Zern MA, Fleischer N, Efrat S.

Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7253-8. Epub 2003 May 19.

Supplemental Content

Loading ...
Support Center